Vildan Bozok Cetintas

Vildan Bozok Cetintas

Auto-generated profile, based on publicly available information

Vildan Bozok Cetintas

Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Türkiye

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
VCVildan B. Cetintas
Vildan B. Cetintas
NBNizar N. Batada
Nizar N. Batada
The PTEN tumor suppressor is the second most commonly inactivated gene across cancer types. While it’s role in PI3K/AKT and DNA damage pathways are clear, increasing evidences suggest that PTEN may also promote anti-tumor immunity. PTEN-deficient tumors are characterized by (i) reduced levels of cytotoxic T cells, helper T cells and NK cells, (ii) elevated pro-oncogenic inflammatory cytokines like CCL2 and (iii) increased levels of immunosuppressive cells such as MDSCs and Tregs. An intriguing possibility is that link between PTEN and anti-tumor immunity is mediated by the interferon signaling pathway. In this review, we summarize the evidences for the mechanistic link between PTEN deficiency and immunosuppressive tumor microenvironment and the interferon signaling pathway. We further discuss how the link between these pathways can be exploited for development of personalized immunotherapy for patients with PTEN deficient tumors.

16 February 2021 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
ZYZafer Yildirim
Zafer Yildirim
OSOyku Semahat Sahin
Oyku Semahat Sahin
SYSeyhan Yazar
Seyhan Yazar
VCVildan Bozok Cetintas
Vildan Bozok Cetintas

10 September 2015 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MKMustafa Kotmakci
Mustafa Kotmakci
VÇVildan Bozok Çetintaş
Vildan Bozok Çetintaş
A new platform for drug, gene and peptide-protein delivery is emerging, under the common name of “extracellular vesicles”. Extracellular vesicles (EVs) are 30-1000 nm-sized cell-derived, liposome-like vesicles. Current research on EVs as nano-delivery systems for small-molecule drugs and genetic material, reveal that these tiny, biologically-derived vesicles carry a great potential to boost the efficacy of many therapeutic protocols. Several features of EVs; from efficacy to safety, from passive to active targeting ability, the opportunity to be biologically or chemically labelled, and most importantly, their eobiotic origin make them promising candidate for development of the next generation personalized nanomedicines. The aim of this article is to provide a view on the current research in which EVs are used as drug/genetic material delivery systems. Their application areas, drug loading and targeting strategies, and biodistribution properties are discussed.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

28 August 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
VÇVildan Bozok Çetintaş
Vildan Bozok Çetintaş
AVAslı Tetik Vardarlı
Aslı Tetik Vardarlı
ZDZekeriya Duzgun
Zekeriya Duzgun
BKBurçin Tezcanlı Kaymaz
Burçin Tezcanlı Kaymaz
EAEda Acikgoz
Eda Acikgoz
ZEZuhal Eroğlu
Zuhal Eroğlu

1 March 2012 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
VCVildan B. Cetintas
Vildan B. Cetintas
AKAli S. Kucukaslan
Ali S. Kucukaslan
BKBuket Kosova
Buket Kosova
AVAslı Tetik Vardarlı
Aslı Tetik Vardarlı
NSNur Selvi
Nur Selvi
ZEZuhal Eroglu
Zuhal Eroglu

30 May 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
BKBurçin Tezcanlı Kaymaz
Burçin Tezcanlı Kaymaz
VÇVildan Bozok Çetintaş
Vildan Bozok Çetintaş
ÇAÇağdaş Aktan
Çağdaş Aktan
BKBuket Kosova
Buket Kosova